Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
ABSTRACT Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded
This demonstrates a disease-modifying effect, very similar to the Bydureon phase II trial results
Among these trials, one involving 36 patients with T2DM did not show any difference from baseline on the MMSE and MoCA after liraglutide at 16 weeksalthough all participants had preserved cognitive function at baseline, while an improvement on tests for delayed memory (possibly mediated by left hippocampal activation), attention and executive function was noted 42
In fact, one recent propensity-matched analysis of non-diabetic patients found that GLP-1 use was associated with a lower incidence of UTI, 8.8% compared to 13.3% in the control group
